SST and neoplasm: Previous efforts to develop metabolically robust pansomatostatin-like radioligands for cancer theranostics were driven by the co-expression of SST1–5Rs in different combinations in NET and other tumor lesions [8,13,14,15,16,17,18,27,28,31,43].